

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:
KEVIN B. LAURENCE
ONE UTAH CENTER
201 SO. MAIN STREET, SUITE 1100
SALT LAKE CITY, UT 84111

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

		Date of mailing (day/month/year)	25 JAN 2005
Applicant's or agent's file reference 50821-15 PCT		FOR FURTHER ACTION See paragraph 2 below	
International application No. PCT/US04/10639	International filing date (day/month/year) 07 April 2004 (07.04.2004)	Priority date (day/month/year) 07 April 2003 (07.04.2003)	
International Patent Classification (IPC) or both national classification and IPC IPC(7): C07D 239/36, 239/91 and US Cl.: 544/287, 319			
Applicant NPS PHARMACEUTICALS, INC.			

1. This opinion contains indications relating to the following items:

<input checked="" type="checkbox"/>	Box No. I	Basis of the opinion
<input type="checkbox"/>	Box No. II	Priority
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/>	Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/>	Box No. VI	Certain documents cited
<input type="checkbox"/>	Box No. VII	Certain defects in the international application
<input type="checkbox"/>	Box No. VIII	Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Deepak Rao  Telephone No. 571-272-1600
--	--

Form PCT/ISA/237 (cover sheet) (January 2004)

BEST AVAILABLE COPY

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/10639

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

a sequence listing
 table(s) related to the sequence listing

b. format of material

in written format
 in computer readable form

c. time of filing/furnishing

contained in international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.

3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/10639

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>5-17, 22-37, 41-42</u>	YES
	Claims <u>1-4, 18-21, 38-40</u>	NO
Inventive step (IS)	Claims <u>5-17, 22-37, 41-42</u>	YES
	Claims <u>1-4, 18-21, 38-40</u>	NO
Industrial applicability (IA)	Claims <u>1-42</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and explanations:

Claims 1-4, 18-21 and 38-40 lack novelty under PCT Article 33(2) as being anticipated by US 5,378,678. The instantly claimed method of preparing pyrimidin-4-one compounds reads on the reference disclosed method, see the reaction taught in col. 5, lines 62-67 of the reference.

Claims 1-4, 18-21 and 38-40 lack an inventive step under PCT Article 33(3) as being obvious over US 5,378,678. The reference teaches a method of preparing pyrimidin-4-one compounds, see the reaction scheme in col. 5, lines 62-67. One of ordinary skill would have been motivated to modify the reference method to prepare the claimed compounds with the reasonable expectation of obtaining structurally analogous compounds from the analogous process.

Claims 5-17, 22-37 and 41-42 meet the criteria of novelty and inventive step set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a method comprising the steps recited in these claims. The reference does not specifically teach or fairly suggest the intermittent steps to prepare pyrimidin-4-one compounds.

Claims 1-42 meet the criteria set out in PCT Article 33(4) because the claimed method is disclosed to be useful in preparing biologically active compounds, and thus meet the requirement of industrial applicability because the subject matter claimed can be made or used in industry.